Zobrazeno 1 - 9
of 9
pro vyhledávání: '"David Hockenbery"'
Autor:
Sandi L. Navarro, Zihan Zheng, Timothy W. Randolph, Ryotaro Nakamura, Brenda M. Sandmaier, David Hockenbery, Jeannine S. McCune
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 11, Pp 2772-2780 (2022)
Abstract Biomarker‐guided dosing may improve the efficacy and toxicity of cyclophosphamide (CY); however, clinical studies evaluating their association with the area under the plasma concentration–time curve (AUC) of CY and its metabolites are ti
Externí odkaz:
https://doaj.org/article/034d5c4902d8493c9cf868fe1012af57
Autor:
Jeannine S. McCune, Ryotaro Nakamura, Denis O’Meally, Timothy W. Randolph, Brenda M. Sandmaier, Aleksandra Karolak, David Hockenbery, Sandi L. Navarro
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 5, Pp 1215-1224 (2022)
Abstract The widely used alkylating agent cyclophosphamide (CY) has substantive interpatient variability in the area under the curve (AUC) of it and its metabolites. Numerous factors may influence the drug‐metabolizing enzymes that metabolize CY to
Externí odkaz:
https://doaj.org/article/fe9f7319ce1b423986ecf0e94f900ca7
Autor:
Josep Tarragó-Celada, Carles Foguet, Míriam Tarrado-Castellarnau, Silvia Marin, Xavier Hernández-Alias, Jordi Perarnau, Fionnuala Morrish, David Hockenbery, Roger R. Gomis, Eytan Ruppin, Mariia Yuneva, Pedro de Atauri, Marta Cascante
Publikováno v:
Cancers, Vol 13, Iss 3, p 425 (2021)
With most cancer-related deaths resulting from metastasis, the development of new therapeutic approaches against metastatic colorectal cancer (mCRC) is essential to increasing patient survival. The metabolic adaptations that support mCRC remain undef
Externí odkaz:
https://doaj.org/article/31dfe6e567b7432b9e6962b72a68148e
Publikováno v:
PLoS ONE, Vol 8, Iss 2, p e56884 (2013)
Increased glycolysis is a hallmark of cancer metabolism, yet relatively little is known about this phenotype at premalignant stages of progression. Periodic ischemia occurs in the premalignant condition Barrett's esophagus (BE) due to tissue damage f
Externí odkaz:
https://doaj.org/article/4243f60a6ee84df7b01551ec4c06eb5b
Autor:
Erica M. Storm, Dimitrios Makraki, Genevieve I. Lin, Laura C. Kennedy, Eshana E. Shah, Amanda I. Phipps, Iris W. Liou, David Hockenbery, Petros Grivas, Ali R. Khaki
Publikováno v:
Cancer Research. 82:1981-1981
Introduction: Immune-related hepatitis (irH) is a serious but unpredictable immune-related adverse event of checkpoint inhibitor (CPI) therapy. The impact of underlying liver pathology, including liver cirrhosis or metastasis, on the incidence of irH
Autor:
Mark J, Margres, Manuel, Ruiz-Aravena, Rodrigo, Hamede, Kusum, Chawla, Austin H, Patton, Matthew F, Lawrance, Alexandra K, Fraik, Amanda R, Stahlke, Brian W, Davis, Elaine A, Ostrander, Menna E, Jones, Hamish, McCallum, Patrick J, Paddison, Paul A, Hohenlohe, David, Hockenbery, Andrew, Storfer
Publikováno v:
Genetics
Spontaneous tumor regression has been documented in a small proportion of human cancer patients, but the specific mechanisms underlying tumor regression without treatment are not well understood. Tasmanian devils are threatened with extinction from a
Autor:
Terri Iwata, Julita Ramirez, Daciana Margineantu, David Hockenbery, Mark Tsang, Brian M Iritani
Publikováno v:
The Journal of Immunology. 196:122.5-122.5
Mechanistic target of Rapamycin (mTOR) senses diverse environmental conditions including nutrient, growth factor and stress conditions, to regulate cellular growth, division, and differentiation. Studies examining the role of mTOR signaling in immune
Autor:
Stephen J. Lockett, Xiao Huan Liang, Salvatore Mungal, Andrea Ayscue, Brian Herman, David Hockenbery, John D. Meissner, Pawel Wodnicki
Publikováno v:
Journal of Cellular Biochemistry. 57:509-521
Bcl-2 protein expression has been found to block apoptosis and its overexpression has been implicated in lymphoid malignancies where the chromosomal translocation t(14;18) is present. In this study we investigated bcl-2 transcription and protein expr
Publikováno v:
The Journal of Immunology. 190:174.10-174.10
Folliculin interacting protein-1 (Fnip1) is a cytoplasmic protein originally discovered through its interaction with Folliculin (Flcn), a tumor suppressor mutated in the hamartoma disorder Birt-Hogg Dubé syndrome. Fnip1 and Flcn both interact with